|Table of Contents|

Efficacy and safety analysis of apatinib in the real-world treatment of metastatic gastric cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2020 02
Page:
264-267
Research Field:
Publishing date:

Info

Title:
Efficacy and safety analysis of apatinib in the real-world treatment of metastatic gastric cancer
Author(s):
Zhou Jianhong; Chen Haihui; Huang Haixin; Chen Shaojun; Luo Wenping; Hua Li; Liu Chunlin
Department of Oncology,Fourth Affiliated Hospital of Guangxi Medical University,Guangxi Liuzhou 545005,China.
Keywords:
apatinib; stomach neoplasms; adverse reaction; real-world; treatment efficacy
PACS:
R735.2
DOI:
10.3969/j.issn.1672-4992.2020.02.020
Abstract:
Objective:To understand the efficacy and safety of apatinib in the real-world treatment of metastatic gastric cancer,and to analyze the factors that affect the efficacy of apatinib.Methods:We collected patients with metastatic gastric cancer who used apatinib in our hospital from November 2014 to May 2018.All patients had at least one cycle apatinib,with dose range from 250 mg to 850 mg,and a record of efficacy and safety assessments.Response Evaluation Criteria in Solid Tumors,version 1.1 and Common Terminology Criteria for Adverse Events,version 4.0 were used to evaluate efficacy and adverse effects．Results:A total of 52 patients were included in the analysis,with a median age of 65 years (range,35~89 years).Patients who early (less than 2 lines) used apatinib were 38 cases,accounting for 73.1%.the PS score was more than 2 shared a total of 8 patients,accounting for 15.4%.The partial response (PR) using apatinib treatment was 9.6%,and the disease control rate was 55.8%.The single factor analysis showed that older age (over 65 years) (P=0.028),less than 2 lines (P=0.037) and use of non-Oncology department (P=0.016) are associated with better efficacy.98.07% of patients had different levels of drug-related adverse reactions in the course of treatment.The most common III-IV grade toxicity reactions were hand-foot syndrome (9.6%),leukopenia (5.8%) and proteinuria (5.8%),and there were no deaths due to drug-related adverse effects.Conclusion:Apatinib is safe in real-world treatment for metastatic gastric cancer.Patients with earlier use of apatinib,benefit more.

References:

［1］Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015［J］.CA Cancer J Clin,2016,66(2):115-132.
［2］Li J,Qin S,Xu J,et al.Randomized,double-blind,placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction［J］.J Clin Oncol,2016,34(13):1448-1454.
［3］Li J,Qin S,Xu J,et al.Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: Results from a randomized,placebo-controlled,parallel-arm,phase II trial［J］.J Clin Oncol,2013,31(26):3219-3225.
［4］QIN SK,LI J.Expert consensus on clinical application of apatinib in the treatment of gastric cancer［J］.Chinese Clinical Oncology,2015,20(9):841-847.［秦叔逵,李进.阿帕替尼治疗胃癌的临床应用专家共识［J］.临床肿瘤学杂志,2015,20(9):841-847.］
［5］HAN TT,SHI MW,WANG F,et al.Clinic observation of apatinib in treatm ent of advanced gastric carcinoma［J］.Modern Oncology,2018,26(4):557-559.［韩婷婷,石明伟,王凡,等.阿帕替尼治疗晚期胃癌的临床疗效观察［J］.现代肿瘤医学,2018,26(4):557-559.］
［6］Watanabe H,Okada M,Kaji Y,et al.New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)［J］.Eur J Cancer,2009,45(2):228-247.
［7］Davies J,Patel M,Gridelli C,et al.Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies［J］.PLoS One,2017,12(4):e0175679.
［8］Williamson TR，Barrett GV.Feasibility of measuring eye movements in real-world and simulated driving situations［J］.Percept Mot Skills,1966,23（1）:329-330.
［9］Araya T,Kita T,Ueda T,et al.Real-world evidence of safety and efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel in patients with advanced non-small cell lung cancer and preexisting interstitial lung disease:A retrospective study［J］.Can Respir J,2019:5315903.
［10］Germonpré P,Van den Wyngaert T.Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness,safety and tolerability［J］.PLoS One,2019,14(4):e0215135.
［11］Fanotto V,Fornaro L,Bordonaro R,et al.Second-line treatment efficacy and toxicity in older vs non-older patients with advanced gastric cancer: A multicentre real-world study［J］.J Geriatr Oncol,2018: S1879-4068(18)30300-X.
［12］Basch E,Schrag D.The evolving uses of "real-world" data［J］.JAMA,2019,321(14):1359-1360.
［13］Jarow JP,Lavange L,Woodcock J.Multidimensional evidence generation and FDA regulatory decision making: Defining and using "real-world" data［J］.JAMA,2017,318(8):703-704.
［14］Malas M,Arhuidese I,Qazi U,et al.Perioperative mortality following repair of abdominal aortic aneurysms:Application of a randomized clinical trial to real-world practice using a validated nationwide data set［J］.JAMA Surg 2014,149(12):1260-1265.
［15］HE SH,LIU ZB,SU X,et al.Efficacy of apatinib and its effect on quality of life of elderly patients with advanced gastric cancer［J］.Anti-tumor Pharmacy,2018,8(5):740-747.［贺生红,刘志波,苏雪,等.阿帕替尼对老年晚期胃癌患者生活质量的影响及疗效分析［J］.肿瘤药学,2018,8(5):740-747.］
［16］Bang YJ,Van CE,Feyereislova A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3,open-label,randomised controlled trial.［J］.Lancet,2010,376(9742):687-697.
［17］Wilke H,Muro K,Van CE,et al.Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind,randomised phase 3 trial［J］.Lancet Oncol,2014,15(11):1224-1235

Memo

Memo:
广西壮族自治区卫生和计划生育委员会自筹经费科研课题（编号：Z20180505）
Last Update: 2019-11-29